Unlocking the Immune System: Advances in Next-generation Immunotherapy for Lung Cancer

Area of Science:

• Oncology
• Immunotherapy
• Nanotechnology

Background:

• Lung cancer is a leading cause of cancer mortality due to molecular heterogeneity and an immunosuppressive tumor microenvironment.
• Existing treatments face challenges with resistance, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review recent advances in lung cancer treatment, focusing on immune checkpoint inhibitors (ICIs) and novel drug delivery systems.
• To highlight the role of predictive biomarkers and emerging technologies like artificial intelligence in personalized lung cancer management.

Main Methods:

• Review of clinical trials involving immune checkpoint inhibitors (e.g., Nivolumab, Pembrolizumab, Durvalumab) and bispecific combinations.
• Exploration of nanotechnology applications (e.g., polymer nanoparticles, smart hydrogels) for targeted drug delivery.
• Analysis of predictive biomarkers (PD-L1, TMB, ctDNA, radiomics) for patient selection and response assessment.

Main Results:

• ICIs targeting PD-1, PD-L1, and CTLA-4 represent a significant advancement in treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
• Nanotechnology enables targeted drug delivery, increasing local concentration and reducing systemic toxicity.
• Predictive biomarkers are crucial for real-time patient selection and treatment response monitoring.

Conclusions:

• Despite progress, challenges like immunotherapy resistance and immune-related adverse events (irAEs) persist.
• Integration of novel biomarkers, precision technologies, and AI is essential for overcoming resistance and optimizing personalized lung cancer care.
• Continued research is vital for developing effective combination therapies and individualized treatment strategies to improve survival rates and patient experiences.